AUPH
Aurinia Pharmaceuticals Inc.
$16.07
-0.01
(-0.06%)
Mkt Cap
2.07B
Volume
968,165
52W Range
10.34-19.25
Sector
Healthcare
Beta
1.41
EPS (TTM)
2.36 USD
P/E Ratio
6.81
Revenue (TTM)
311.51M USD
Rev Growth (5Y)
+41.4%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$34.51
Undervalued
strong signal
53.4% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 283.06M | 235.13M | 175.51M | 134.03M | 45.60M | 50.12M | 318,000 | 463,000 | 420,000 | 173,000 | 235,000 | 278,000 |
| Net Income | 287.20M | 5.75M | (78.02M) | (108.18M) | (180.97M) | (102.68M) | (88.39M) | (64.12M) | (70.79M) | (23.30M) | (18.61M) | (16.65M) |
| EPS | 2.14 | 0.04 | -0.54 | -0.76 | -1.40 | -0.87 | -1.33 | -0.76 | -0.92 | -0.66 | -0.58 | -0.57 |
| Free Cash Flow | 135.41M | 44.11M | (34.18M) | (79.82M) | (159.19M) | (77.20M) | (63.69M) | (51.69M) | (41.19M) | (18.74M) | (17.82M) | (16.99M) |
| FCF / Share | 1.01 | 0.31 | -0.24 | -0.56 | -1.23 | -0.65 | -0.68 | -0.61 | -0.54 | -0.53 | -0.55 | -0.59 |
| Operating CF | 135.66M | 44.39M | (33.46M) | (79.53M) | (157.69M) | (69.86M) | (63.59M) | (51.61M) | (41.17M) | (18.71M) | (17.77M) | (16.90M) |
| Total Assets | 751.59M | 550.64M | 548.06M | 470.86M | 543.37M | 463.66M | 324.30M | 145.86M | 189.85M | 57.00M | 33.57M | 52.38M |
| Total Debt | 74.81M | 79.37M | 97.61M | 8.09M | 8.74M | 8.41M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 80.21M | 83.43M | 48.88M | 94.17M | 231.90M | 272.35M | 306.02M | 117.97M | 165.63M | 39.65M | 5.76M | 22.71M |
| Book Value | 581.33M | 377.48M | 377.95M | 405.44M | 479.09M | 407.75M | 298.60M | 112.58M | 165.74M | 35.95M | 19.96M | 45.11M |
| Return on Equity | 0.49 | 0.02 | -0.21 | -0.27 | -0.38 | -0.25 | -0.30 | -0.57 | -0.43 | -0.65 | -0.93 | -0.37 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83.22M | 77.70M | 77.11M | 73.47M | 70.01M | 62.47M | 59.87M | 67.77M | 57.19M | 50.30M | 45.09M | 54.52M |
| Net Income | 37.41M | 34.35M | 210.79M | 31.55M | 21.51M | 23.34M | 1.43M | 14.35M | 722,000 | (10.75M) | (26.88M) | (13.45M) |
| EPS | 0.29 | 0.26 | 1.58 | 0.23 | 0.16 | 0.16 | 0.01 | 0.10 | 0.01 | -0.07 | -0.19 | -0.09 |
| Free Cash Flow | 52.17M | 32.52M | 44.50M | 44.38M | 44.14M | 1.28M | 30.06M | 16.94M | 15.71M | (18.61M) | 14.25M | (13.17M) |
| FCF / Share | 0.40 | 0.25 | 0.33 | 0.33 | 0.32 | 0.01 | 0.21 | 0.12 | 0.11 | -0.13 | 0.10 | -0.09 |
| Operating CF | 52.17M | 32.56M | 44.57M | 44.45M | 44.24M | 1.30M | 30.11M | 17.03M | 15.84M | (18.60M) | 14.31M | (13.28M) |
| Total Assets | 792.26M | 724.00M | 751.59M | 527.53M | 502.56M | 504.85M | 550.64M | 549.36M | 523.53M | 516.63M | 548.06M | 555.01M |
| Total Debt | 60.42M | 68.64M | 74.81M | 78.21M | 81.83M | 77.91M | 79.37M | 87.85M | 85.98M | 88.54M | 97.61M | 93.21M |
| Cash & Equiv | 179.83M | 41.01M | 80.21M | 73.19M | 53.00M | 66.43M | 83.43M | 37.14M | 33.41M | 64.46M | 48.88M | 46.40M |
| Book Value | 614.86M | 567.63M | 581.33M | 365.77M | 335.30M | 350.19M | 377.48M | 388.00M | 364.62M | 359.48M | 377.95M | 391.88M |
| Return on Equity | 0.06 | 0.06 | 0.36 | 0.09 | 0.06 | 0.07 | 0.00 | 0.04 | 0.00 | -0.03 | -0.07 | -0.03 |
AUPH News
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Settles Patent Litigation with Teva
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Playing The Biotech Breakout With Insiders
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why